Auris Medical Holding AG (NASDAQ:EARS) saw unusually-high trading volume on Tuesday . Approximately 160,492 shares were traded during trading, an increase of 4% from the previous session’s volume of 154,259 shares.The stock last traded at $3.87 and had previously closed at $3.79.

EARS has been the topic of a number of research analyst reports. Leerink Swann restated a “buy” rating on shares of Auris Medical Holding AG in a research note on Thursday, May 12th. Jefferies Group reiterated a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th. Finally, Zacks Investment Research upgraded Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Tuesday, July 12th.

The stock’s market cap is $131.82 million. The company’s 50 day moving average price is $4.06 and its 200 day moving average price is $3.95.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.